Jasper Therapeutics (JSPR) news
Recent news
Jasper Therapeutics - First FSGS patient in phase 2 study expected to be dosed in Q1 2027
Jasper Therapeutics, Inc. (Nasdaq: JSPR) has announced that the first patient in the focal segmental glomerulosclerosis (FSGS) cohort of its Phase 2 basket study of vensobafusp alfa (KP104) is expected to be dosed in Q1 2027 . This follows the completion of enrollment for the IgA nephropathy (IgAN)…
AInvest Wire · 6h agoJasper Therapeutics - Initial interim data from IGAN study expected by year-end 2026
AInvest Wire · 6h agoJasper Therapeutics, Inc.: William Blair resumes coverage with outperform rating
AInvest Wire · 1d agoRPT-Jasper Therapeutics announces commencement of an offer to purchase outstanding warrants
Jasper Therapeutics has announced the commencement of an offer to purchase its outstanding warrants, according to a recent filing. The company has initiated the tender offer as part of its ongoing efforts to manage its capital structure and enhance shareholder value. Specific terms of the offer,…
AInvest Wire · Oct 7, 2026Jasper Therapeutics - Offer purchase price is $0.32 in cash per warrant
AInvest Wire · Oct 7, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.